Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant

American Journal of Hematology
Brenda M SandmaierOlga Frankfurt

Abstract

FLT3-ITD-mutated acute myeloid leukemia (AML) has very high risk of relapse and is associated with poor outcome following allogeneic hematopoietic-cell transplant (allo-HCT). This two-part, phase 1, multicenter, open-label, sequential-group, dose-escalation study aimed to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and safety/tolerability of quizartinib, a selective and highly potent FLT3 inhibitor, when administered as maintenance therapy after allo-HCT. Thirteen subjects with documented FLT3-ITD-mutated AML in morphological remission following allo-HCT received one of two quizartinib dihydrochloride dose levels (DL): 40 mg/d (DL1; n = 7) and 60 mg/d (DL2; n = 6), administered orally in 28-day cycles for up to 24 cycles. Median age of participants was 43 years. All subjects received human leukocyte antigen (HLA)-matched allo-HCT. One subject treated at DL1 and 1 treated at DL2 had DLTs that required drug interruption (grade 3 gastric hemorrhage and grade 3 anemia, respectively). Ten subjects (77%) received quizartinib for >1 year; 5 (38%) completed 24 cycles. Four subjects (31%) discontinued quizartinib due to adverse events. One subject (8%) experienced relapse during cycle 1 and discontinued trea...Continue Reading

References

Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L SieversUNKNOWN Mylotarg Study Group
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Feb 22, 2007·Blood·Martin BornhäuserUNKNOWN AML SHG 96 study group
Sep 10, 2008·Critical Reviews in Oncology/hematology·Shabbir M H AlibhaiMark D Minden
Nov 3, 2009·Leukemia Research·Farhad RavandiMiloslav Beran
Dec 5, 2009·Best Practice & Research. Clinical Haematology·Maria R Baer
Feb 18, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Amy E DeZernMark Levis
Nov 19, 2011·Hematology/oncology Clinics of North America·David Grimwade, Krzysztof Mrózek
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Salut BrunetVanderson Rocha
Jul 7, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel WeisdorfMary Eapen
Mar 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rainer StorbBrenda M Sandmaier
Aug 24, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M F FeyUNKNOWN ESMO Guidelines Working Group
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesMark Levis
Jun 3, 2014·Therapeutic Advances in Hematology·Seth A WanderAmir T Fathi
Sep 23, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yi-Bin ChenRobert Soiffer
Sep 10, 2015·Blood·Christoph SchmidUNKNOWN Acute Leukemia Working Party of the European Group of Blood and Bone Marrow Transplantation
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Jan 15, 2016·Current Opinion in Hematology·Jonathan Canaani, Selina M Luger
Jan 20, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gary J SchillerPinkal Desai
Jul 2, 2016·Blood Cancer Journal·I De Kouchkovsky, M Abdul-Hay
Jan 21, 2017·Journal of the National Cancer Institute·Charlie Schmidt
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner

❮ Previous
Next ❯

Citations

Apr 19, 2019·Leukemia & Lymphoma·Kiran Naqvi, Farhad Ravandi
Apr 5, 2019·American Journal of Hematology·Bruno C MedeirosDaniel A Pollyea
Apr 30, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark J LevisUNKNOWN Blood and Marrow Transplant Clinical Trials Network
Jun 25, 2019·Expert Review of Hematology·Eran Tallis, Gautam Borthakur
Jan 11, 2020·Leukemia·Ahmad I AntarAli Bazarbachi
Feb 9, 2020·Current Hematologic Malignancy Reports·Bradley D Hunter, Yi-Bin Chen
Jul 17, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas BurchertStephan K Metzelder
Sep 19, 2019·Biomarker Research·Juanjuan ZhaoDelong Liu
Jun 2, 2020·Biomarker Research·Jifeng YuYongping Song
Dec 6, 2018·Journal of Hematology & Oncology·Mei WuXiongpeng Zhu
Jul 28, 2019·Current Hematologic Malignancy Reports·Courtney DiNardo, Curtis Lachowiez
Aug 21, 2019·American Journal of Hematology·Matteo MolicaTapan M Kadia
Feb 28, 2020·International Journal of Molecular Sciences·Stephen S Y Lam, Anskar Y H Leung
Aug 11, 2020·Expert Opinion on Pharmacotherapy·Alejandro Garcia-Horton, Karen Wl Yee
May 19, 2020·Current Cancer Drug Targets·Francesca L HoganSteven Knapper
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aideen T O'Neill, Ronjon Chakraverty
Sep 24, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bhagirathbhai DholariaArnon Nagler
Jan 12, 2021·Frontiers in Oncology·Vanessa E Kennedy, Catherine C Smith
Apr 10, 2021·Blood Reviews·Marcos de LimaGert Ossenkoppele
Aug 18, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pierre-Yves DumasVanessa Desplat
Jan 26, 2022·Expert Opinion on Emerging Drugs·Antonio Solana-AltabellaPau Montesinos

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies

Clinical Trials Mentioned

NCT01468467
NCT02039726
NCT02668653

Software Mentioned

SAS
QuANTUM

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.